PTGX Stock Overview
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Protagonist Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.98 |
| 52 Week High | US$30.10 |
| 52 Week Low | US$7.24 |
| Beta | 1.85 |
| 1 Month Change | -16.64% |
| 3 Month Change | -38.50% |
| 1 Year Change | 104.09% |
| 3 Year Change | -14.97% |
| 5 Year Change | 65.01% |
| Change since IPO | 45.13% |
Recent News & Updates
Recent updates
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04
Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04How Many Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Did Insiders Buy, In The Last Year?
Feb 09We're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn
Dec 18Dosing underway in Protagonist Therapeutics' early stage study with PN-235
Dec 16Protagonist Therapeutics prices $100M stock offering
Dec 11Protagonist Janssen Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 04Protagonist Therapeutics, Janssen advance oral IL-23 receptor antagonists program
Oct 30Shareholder Returns
| PTGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.1% | -1.3% | -2.9% |
| 1Y | 104.1% | 10.9% | 15.3% |
Return vs Industry: PTGX exceeded the US Biotechs industry which returned 10.8% over the past year.
Return vs Market: PTGX exceeded the US Market which returned 13.8% over the past year.
Price Volatility
| PTGX volatility | |
|---|---|
| PTGX Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in US Market | 14.4% |
| 10% least volatile stocks in US Market | 2.6% |
Stable Share Price: PTGX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: PTGX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 106 | Dinesh Patel | https://www.protagonist-inc.com |
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics, Inc. Fundamentals Summary
| PTGX fundamental statistics | |
|---|---|
| Market Cap | US$976.86m |
| Earnings (TTM) | -US$137.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.1x
P/E RatioIs PTGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTGX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$137.61m |
| Earnings | -US$137.61m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PTGX perform over the long term?
See historical performance and comparison